These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32594504)

  • 1. Letter To The Editor - Drug Eruption After Sustained Release Naltrexone Pellet Implantation.
    Ak S; Can Gürel Ş
    Turk Psikiyatri Derg; 2020; 31(2):146-147. PubMed ID: 32594504
    [No Abstract]   [Full Text] [Related]  

  • 2. Naltrexone-induced Nicolau syndrome masquerading as cutaneous abscess.
    Perli D; Martone C; Rapose A
    BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23242099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-acting depot formulations of naltrexone for heroin dependence: a review.
    Krupitsky EM; Blokhina EA
    Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
    Fishman M
    Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of subcutaneous, drug-releasing implants for the treatment of opioid drug addiction.
    Bal C; Rappersberger K; Posch C
    J Dtsch Dermatol Ges; 2017 Dec; 15(12):1232-1234. PubMed ID: 28841773
    [No Abstract]   [Full Text] [Related]  

  • 7. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.
    Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE
    Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lichenoid drug eruption associated with bisoprolol transdermal patches.
    Asano A; Nakai K; Tsuruta D
    Contact Dermatitis; 2022 Feb; 86(2):139-141. PubMed ID: 34687067
    [No Abstract]   [Full Text] [Related]  

  • 9. Concerns about injectable naltrexone for opioid dependence.
    Wolfe D; Carrieri MP; Dasgupta N; Wodak A; Newman R; Bruce RD
    Lancet; 2011 Apr; 377(9776):1468-70. PubMed ID: 21529930
    [No Abstract]   [Full Text] [Related]  

  • 10. Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.
    Lobmaier PP; Kunøe N; Gossop M; Waal H
    CNS Neurosci Ther; 2011 Dec; 17(6):629-36. PubMed ID: 21554565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Letter to the Editor: Shopping frenzy induced by naltrexone--a paradoxical effect in bipolar disorder?
    Losekam S; Kluge I; Nittel KS; Kircher T; Konrad C
    Psychol Med; 2013 Apr; 43(4):895. PubMed ID: 23302184
    [No Abstract]   [Full Text] [Related]  

  • 12. [Naltrexone--prevention of recurrence in narcotic dependence and in alcoholism].
    Poser W; Ehrenreich H
    Internist (Berl); 1996 Oct; 37(10):1061-7; discussion 1067. PubMed ID: 9019453
    [No Abstract]   [Full Text] [Related]  

  • 13. Extended-release intramuscular naltrexone.
    Swainston Harrison T; Plosker GL; Keam SJ
    Drugs; 2006; 66(13):1741-51. PubMed ID: 16978037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems.
    Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D
    J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection.
    Mitchell MC; Memisoglu A; Silverman BL
    J Stud Alcohol Drugs; 2012 Nov; 73(6):991-7. PubMed ID: 23036218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unplanned admissions to two Sydney public hospitals after naltrexone implants.
    Little M; Murray LM
    Med J Aust; 2008 Oct; 189(8):469; author reply 470-1. PubMed ID: 19024885
    [No Abstract]   [Full Text] [Related]  

  • 17. Morphine/naltrexone.
    Duggan ST; Scott LJ
    CNS Drugs; 2010 Jun; 24(6):527-38. PubMed ID: 20443648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blame the counselling, not the implant. A response to Oliver, Horspool & Keen (2005).
    Kunøe N; Lobmaier P
    Addiction; 2005 Jul; 100(7):1027-8; author reply 1028-9. PubMed ID: 15955020
    [No Abstract]   [Full Text] [Related]  

  • 19. Unplanned admissions to two Sydney public hospitals after naltrexone implants.
    Lloyd-Jones DM
    Med J Aust; 2008 Oct; 189(8):468-9; author reply 470-1. PubMed ID: 18928445
    [No Abstract]   [Full Text] [Related]  

  • 20. Rapid opioid detoxification in Australia.
    Reece S
    Acad Emerg Med; 2002 Sep; 9(9):960-2. PubMed ID: 12208687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.